Therapeutic effects of cefozopran on polymicrobial infections associated with Enterococcus faecalis in a Rat pyometra model.
Enterococcus faecalis plays an important role as a pathogen in polymicrobial infections. We evaluated the efficacy of cefozopran (CZOP) using polymicrobial pyometra rats. Rats were infected with a mixed intrauterine inoculation of E. faecalis plus either Bacteroides fragilis or Prevotella bivia (minimal inhibitory concentration of CZOP; E. faecalis: 6.25 micrograms/ml, B. fragilis: 12.5 micrograms/ml, P. bivia: 12.5 micrograms/ml). Immediately after inoculating 10(5) CFU of each organism/rat, CZOP (either 40 mg/kg, i.v., q.i.d., for 5 days or 80 mg/kg, i.v., b.i.d., for 5 days) was administered. The intrauterine inflammatory change and bacterial counts in the CZOP-treated group were compared with those in the nontreated control group. CZOP significantly (p < 0.01) decreased the bacterial counts except for B. fragilis in the regimen of 80 mg/kg b.i.d. However, the 40 mg/kg, q.i.d., regimen significantly (p < 0.05) reduced bacterial counts compared to 80 mg/kg, b.i.d. These results suggest that CZOP in a more divided dose is efficacious for the treatment of polymicrobial infections associated with E. faecalis in pyometra.
Mikamo
H
H
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Kawazoe
K
K
Sato
Y
Y
Izumi
K
K
Tamaya
T
T
D000818:Animals; D016866:Bacteroidaceae Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001442:Bacteroides Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001441:Bacteroides fragilis / Q000187:drug effects / Q000302:isolation & purification; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004717:Endometrium / Q000187:drug effects / Q000382:microbiology; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D009215:Myometrium / Q000187:drug effects / Q000382:microbiology; D018720:Prevotella / Q000187:drug effects / Q000302:isolation & purification; D051381:Rats; D017207:Rats, Sprague-Dawley; D014591:Uterine Diseases / Q000188:drug therapy* / Q000382:microbiology*; D000097586:Cefozopran
D002511:Cephalosporins; D000097586:Cefozopran